Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.

L Schmidt, Andrew; D Tucker, Matthew; Bakouny, Ziad; Labaki, Chris; Hsu, Chih-Yuan; Shyr, Yu; J Armstrong, Andrew; M Beer, Tomasz; R Bijjula, Ragneel; A Bilen, Mehmet; F Connell, Cindy; Joseph Dawsey, Scott; Faller, Bryan; Gao, Xin; A Gartrell, Benjamin; Gill, David; Gulati, Shuchi; Halabi, Susan; Hwang, Clara; Joshi, Monika; Raza Khaki, Ali; Menon, Harry; J Morris, Michael; Puc, Matthew; B Russell, Karen; J Shah, Neil; Sharifi, Nima; Shaya, Justin; T Schweizer, Michael; Steinharter, John; M Wulff-Burchfield, Elizabeth; Xu, Wenxin; Zhu, Jay; Mishra, Sanjay; Grivas, Petros; I Rini, Brian; Lyle Warner, Jeremy; Zhang, Tian; K Choueiri, Toni; Gupta, Shilpa; R McKay, Rana

doi:10.1001/jamanetworkopen.2021.34330

Public

Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.

Published in JAMA network open • Nov 1, 2021

NobleIDark:/48914/w1/20260526/2A630088Record on NobleID

Authors:

Andrew L Schmidt

,

Matthew D Tucker

,

Ziad Bakouny

Abstract

Importance: Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissue-based expression of the SARS-CoV-2 coreceptor transmembrane protease, serine 2 (TMPRSS2). Objective: To exam...

Discussions